Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clinical Trial Details

This study is being done to answer the following question: Can we prolong life for patients with advanced kidney cancer, by adding a drug called cabozantinib to another treatment after receiving the standard treatment? 

If you decide to take part in this study, you will receive treatment with ipilimumab and nivolumab every 3 weeks for 4 treatments (lasting about 12 weeks). Then, based on scan results, patients will be treated with either nivolumab or cabozantinib, or nivolumab and cabozantinib for up to 1 year. Treatment will be given until the disease worsens or the side effects become too severe.

After you finish treatment your doctor will continue to follow your condition by getting labs every 6 weeks and scans every 3 months until your disease worsens. Once the disease worsens the labs and scans are no longer required, and your doctor’s office will check in with you once every 6 months for 5 years after you are registered to the trial to see how you are doing.

Key Eligibility: 
  • Open to men and women age 18 or older who have metastatic untreated renal cell carcinoma
  • Detailed eligibility will be reviewed when you contact the study team

Study contact by location

Upper East Side - Manhattan


Amie Patel, RN

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:






Open to Enrollment

Age Group